NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 2018
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
6/8 — Strong
ELEPSIA XR (levetiracetam) by VentriPoint Diagnostics is mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. Approved for epilepsy, seizures. First approved in 2018.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELEPSIA XR is an extended-release oral formulation of levetiracetam, an antiepileptic agent approved for seizure management in epilepsy. The drug's mechanism involves binding to synaptic vesicle protein SV2A, thought to regulate vesicle exocytosis, though the precise antiseizure mechanism remains incompletely understood. It is indicated for epilepsy and seizure disorders.
LOE Approaching1.5 years to LOE
Product is approaching loss of exclusivity (2027), signaling smaller brand team focus and potential transition toward generic defense and lifecycle extension strategies.
Mechanism of Action
mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be…
Indications (2)
Worked on ELEPSIA XR at VentriPoint Diagnostics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.